Appendix Cancer Survival Rates: How Common It Is and What the Numbers Mean
If you have just been told you have appendix cancer, one of the first things you may want to look up is the survival rate. That is a normal thing to want to know. This guide walks through what is known about how common appendix cancer is, what survival numbers actually measure, and why those numbers cannot tell you what will happen to you. We will give you the real figures with their sources, and we will be clear about where the numbers are shaky. Some people want every statistic. Others would rather not read them at all. Both choices are fine, and you can stop reading at any point.
How common is appendix cancer?
Appendix cancer is rare. The classic estimate is about 1 to 2 cases for every 1 million people each year. That number appears in the appendix cancer overview from Cleveland Clinic and in the appendiceal cancer and tumors report from NORD. To put it in plain terms, in a city of 1 million people you might expect only one or two new cases in a year.
Newer counting suggests the true number is higher. The ACPMP Research Foundation appendix cancer overview notes that some research puts the rate at up to about 10 cases per 1 million people per year when every kind of appendiceal tumor is counted. ACPMP also points out that reported cases have gone up over the past decade, partly because doctors and pathologists are better at recognizing and naming these tumors. So estimates vary, and no one has a single exact figure.
Some subtypes have their own counts. Pseudomyxoma peritonei, or PMP, is a buildup of jelly-like mucus in the belly that appendix tumors can cause. ACPMP reports that recent research estimates PMP affects about 3.2 people per 1 million each year. For neuroendocrine tumors, which start in hormone-making cells, the American Cancer Society key statistics page for gastrointestinal neuroendocrine tumors reports that about 8,000 of these tumors are diagnosed each year in the United States across the whole digestive tract, including the appendix. The appendix is one of the common sites, but it is not the most common one.
Most people are middle-aged when they find out. The average age at diagnosis for appendix cancer is roughly 50 to 55 years, and Cleveland Clinic notes that most people are diagnosed in their 50s. Males and females are affected about equally, although some studies show slightly more females, and appendiceal neuroendocrine tumors are more common in females. For digestive tract neuroendocrine tumors as a group, the American Cancer Society reports an average age in the early 60s.
The number of younger adults being diagnosed is climbing, and that is one of the clearest trends in this disease. Research covered by Vanderbilt University Medical Center on rising appendix cancer rates in younger adults used SEER data, the National Cancer Institute's national cancer registry. It found that rates tripled for people born between 1976 and 1984 and quadrupled for people born between 1981 and 1989, compared with a baseline group born between 1941 and 1949. About 1 in 3 people with appendix cancer is under age 50. For colorectal cancer, that figure is closer to 1 in 10.
An earlier Vanderbilt report on appendix cancer survival differences by race in young patients states that the incidence of malignant appendiceal cancer rose 232 percent in the United States, even though the rate of appendix removal surgery stayed steady over the same two decades. Researchers do not yet know why. Better detection is part of it. Something real may also be changing. If you want more background on what raises risk and what does not, see our page on risk factors for appendix cancer.
What is the survival rate for appendix cancer?
Before any number, it helps to know what a survival rate is. A 5-year survival rate is the share of people in a study group who were still alive 5 years after their cancer was found. It is not a countdown clock, and it is not a limit on your life. The National Cancer Institute page on understanding cancer prognosis explains the main kinds of survival statistics. Cancer-specific survival counts only deaths from the cancer itself. Overall survival counts deaths from any cause. Relative survival compares people with the cancer to people without it. Disease-free survival counts people with no sign of cancer after treatment. Two studies can report very different numbers simply because they measured different things.
There is no single survival rate for appendix cancer, because appendix cancer is not one disease. Type, grade, and stage change the picture enormously. Grade describes how abnormal the cells look under a microscope. Cleveland Clinic reports that 5-year survival for low-grade appendix cancer is 67 to 97 percent, and that survival is much lower for aggressive tumors or for disease found late. That is a wide range, and the width is the point. Our pages on appendix cancer stages and appendix cancer facts explain the types and grades in more detail.
Research using the SEER database gives a similarly broad range. The Vanderbilt University Medical Center report on rising appendix cancer rates states that up to 1 of every 2 patients is diagnosed with distant metastatic disease, meaning the cancer has already spread beyond the appendix, and that 5-year survival rates vary between 10 percent and 63 percent depending on the type of tumor and the stage. The reason so many people are diagnosed after spread is physical, not personal. The wall of the appendix is very thin, so tumor cells push through it easily and settle in the belly cavity.
Survival is not equal across groups, and that deserves to be said out loud. In the first study of appendix cancer patterns and survival by race and ethnicity in people under 50, Vanderbilt researchers reported that among 1,652 people diagnosed between ages 20 and 49 from 2000 to 2011, cancer-specific survival 5 years after diagnosis was 77.0 percent for non-Hispanic white patients, 64.5 percent for non-Hispanic Black patients, and 79.2 percent for Hispanic patients. Outcomes were also poorer for men than for women. The researchers found that income and similar social factors did not fully explain the gap between groups, and they are still studying why it exists. If you are a Black patient, this is a fair thing to raise with your team, including asking whether your pathology has been reviewed by a specialist and whether you have been referred to a high-volume center.
Every one of these numbers comes from people treated years ago. The Vanderbilt survival figures above come from people diagnosed between 2000 and 2011. Treatment has moved since then. Cytoreductive surgery with heated chemotherapy in the belly is more widely available, pathology naming is more precise, and more centers do a high volume of these operations. The National Cancer Institute makes this point directly: it takes years to see the benefit of newer treatments, so the statistics a doctor uses may not reflect the care being given today. Numbers lag behind practice.
The last thing to hold onto is that statistics describe groups, not people. A rate of 67 percent does not mean you have 67 percent of a life. It means that out of a large group of people who looked similar on paper, about 67 out of 100 were alive at the 5-year mark. You are not on paper. Your age, your other health conditions, the exact grade of your tumor, how much disease your surgeon can remove, and how your body responds to treatment all matter. Your own oncologist, who has seen your scans and your pathology report, is the only person who can talk with you about your situation, and even then a prognosis is an educated estimate.
Is appendix cancer curable?
For some people, yes. Many low-grade appendiceal neuroendocrine tumors are cured by surgery alone. These tumors are usually small, usually sit at the tip of the appendix, and are often found by accident when the appendix is removed for suspected appendicitis. When the tumor is small, often under 1 to 2 centimeters, the appendectomy that already happened may be the whole treatment, with follow-up scans and blood tests after that. Cleveland Clinic and the ACPMP Research Foundation both describe this pattern.
A low-grade appendiceal mucinous neoplasm, or LAMN, that stays inside the appendix is another situation with strong outcomes. LAMN is not classified as cancer because it cannot travel through lymph nodes or the bloodstream. NORD notes that when a LAMN is confined to the appendix, removing the appendix is enough, and a larger bowel operation is not required. The catch is that a LAMN can still leak mucus-producing cells into the belly, which is how PMP starts, so careful follow-up matters.
For disease that has already spread inside the belly, the picture is more complex but not hopeless. Advanced appendix cancer and PMP were once described as treatable but not curable. That language is changing. The ACPMP Research Foundation reports that cytoreductive surgery with HIPEC, meaning surgery to remove all visible tumor followed by heated chemotherapy washed through the belly cavity, has produced long-term survival in up to 90 percent of patients who have low-grade appendiceal PMP pathology and who are correctly diagnosed and treated early enough. A growing number of people with favorable pathology have gone years with no sign of disease. Our page on appendix cancer treatment options explains these operations in plain language.
Where the tumor is treated makes a real difference, and this is one of the few things patients can act on. Studies gathered on the ACPMP find that a specialist page for appendix cancer and PMP shows that a surgical team reaches the top of its learning curve for this operation only after roughly 130 to 200 or more procedures, and some specialists have done 1,000 or more. ACPMP encourages patients to ask a surgeon how many of these operations they have performed and to seek opinions from at least two or three recognized specialists before choosing.
Higher grade tumors are harder. Poorly differentiated adenocarcinoma and signet ring cell adenocarcinoma grow faster, reach lymph nodes more often, and are harder to remove completely. For these, treatment usually combines surgery with chemotherapy drugs borrowed from colon cancer, because no chemotherapy regimen has been designed specifically for appendix cancer yet. That gap is exactly why research participation matters so much in this disease. Our page on joining a clinical trial for appendix cancer explains how trials work and how to find them.
It also helps to know what doctors mean by the word cure. The National Cancer Institute explains that cure means no trace of cancer and no return, while remission means the signs of cancer are reduced or gone. If someone stays in complete remission for 5 years or more, some doctors will use the word cured, but cells can linger, so most teams say instead that there is no sign of cancer at this time. That is why monitoring continues for years. Bring your questions about your own outlook to your appointments, and use our list of questions to ask your doctor about appendix cancer so you do not have to think them up on the spot. You can also connect with a trained HealthTree Coach if you want help sorting through what you have read.